Arugula Sciences is a clinical-stage biotech company focused on developing advanced therapeutics that utilize the biological properties of human perinatal tissues and cells. Their leading product, Signature Cord Prime™, is an injectable human umbilical cord allograft currently undergoing FDA Phase 1 clinical trials aimed at treating symptomatic knee osteoarthritis. This product is characterized by its compliance with current Good Manufacturing Practices (cGMP) and is standardized for safety, potency, purity, and identity. Additionally, Arugula is advancing its research on Umbilical Cord Mesenchymal Stem Cells (UC-MSCs), which are recognized for their superior therapeutic potential compared to stem cells from other sources. The company is preparing to pursue FDA clinical trials for these cells in the near future.

In addition to their cellular therapies, Arugula Sciences is developing a portfolio of acellular products, including their first acellular drug, SIG002. This product has received FDA clearance for an investigational new drug application and is set to enter a Phase 1 clinical trial to evaluate its safety, tolerability, and preliminary efficacy in patients with symptomatic osteoarthritis. The acellular technologies focus on harnessing the regenerative and immunomodulatory properties of perinatal-derived secretomes, positioning Arugula at the forefront of innovative therapeutic solutions for chronic inflammatory and degenerative diseases.

United States

We are a clinical-stage biotech company dedicated to the discovery, development, and commercialization of advanced therapeutics that leverage the biological properties of human perinatal tissues and cells. All our efforts are made to support patients and help fulfill their unmet clinical needs.

Arugula Sciences

Company Details